Ledipasvir/Tegobuvir/Vedroprevir + Pravastatin = Precautionary

Effect on Concentration

Ledipasvir/Tegobuvir/Vedroprevir
Unknown
Applies within class?
No
Pravastatin
Increase
Applies within class?
No

Pharmacologic Effects

Ledipasvir/Tegobuvir/Vedroprevir
Effect
N/A
Applies within class?
No
Pravastatin
Effect
N/A
Applies within class?
No

Interaction History

N/A

Last Updated 22-Nov-2022

Summary

Sources

ledipasvir/sofosbuvir vs pravastatin, rosuvastatin, gigoxin, or cyclosporine ^

Study Design

The drug-drug interaction potential of ledipasvir (LDV) in combination with vedroprevir (VDV) and tegobuvir (TGV) with pravastatin was evaluated.

Study Results

Co-administration of LDV/VDV/TGV and pravastatin resulted in an increased Cmax and AUC by 166% and 168%, respectively, for pravastatin.Overall incidence of statin-related adverse events in the pooled Phase 2/3 population was similar in HCV-infected patients who did and did not receive statins.Use the lowest possible pravastatin dose and titrate carefully. Close monitoring for statin adverse effects is advised when utilizing this combination.

Study Conclusions

References

P German, Pang PS, L Fang, et al. Drug-drug interaction profile of the fixed dose combination tablet ledipasvir/sofosbuvir. American Association For The Study Of Liver Diseases. Boston, MA. ; 2014.